Biosimilar Development News

  1. Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer 3/27/2025

    Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.

  2. Celltrion's STEQEYMA® (ustekinumab-stba), Now Added To The Costco Member Prescription Program 3/27/2025

    Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member Prescription Program.

  3. Bio-Thera And Dr. Reddy's Execute Exclusive Commercialization Agreement For BAT2206, A Proposed Stelara® Biosimilar, And BAT2506, A Proposed Simponi® Biosimilar, For Southeast Asia 3/27/2025

    Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY| NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

  4. Biosimilars Forum Executive Director Juliana Reed To Speak At Evolution Of Biosimilars Development Workshop 3/26/2025

    Juliana Reed, executive director of the Biosimilars Forum, will speak at the DIA Evolution of Biosimilar Development Workshop on May 21, 2025. Reed will discuss the current state of the biosimilars industry, highlighting the need for Americans to have increased access to lower-cost biosimilars.

  5. African Development Bank Approves EUR 15 Million Loan To Boost Biosimilars' Development And Production In Egypt 3/26/2025

    The Board of Directors of the African Development Bank (the “AfDB”) has approved a EUR 15 million senior corporate loan to Minapharm Pharmaceuticals S.A.E. (Minapharm), a leading biopharmaceutical company in Egypt.

  6. Biosimilars Forum Chair Of Scientific Affairs Committee To Speak At The Festival Of Biologics USA 3/24/2025

    Hillel P. Cohen, Chair of the Scientific Affairs Committee for the Biosimilars Forum, will speak at the Festival of Biologics USA 2025 on April 24, 2025, to discuss importance of streamlining biosimilar development.

  7. Pfizer's IXIFI Will Be Available In Canada As Of April 1, 2025 3/21/2025

    Pfizer Canada is pleased to announce that IXIFI (infliximab for injection) will be available in Canada as of April 1. IXIFI is a biosimilar to Remicade (infliximab.) IXIFI was approved by Health Canada in December 2021 for all eligible indications of the reference product, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease (in adults and pediatric patients 9 years and older), fistulising Crohn’s disease, ulcerative colitis (in adults and pediatric patients 6 years and older), psoriatic arthritis, and plaque psoriasis.

  8. Alvotech Acquires Xbrane's R&D Operations In Sweden And Further Affirms Its Global Leadership Position In Biosimilars Development And Production 3/20/2025

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life science sector.

  9. Xbrane Has Entered Into An Agreement To Sell XB003 (Cimzia Biosimilar Candidate) And Parts Of Its Organization To Alvotech For A Total Consideration Of SEK 275 Million 3/20/2025

    Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees and laboratory equipment, to Alvotech for a total consideration of approximately SEK 275 million.

  10. STEQEYMA® (ustekinumab-stba), A Biosimilar To STELARA® (ustekinumab), Now Available In The United States 3/12/2025

    Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.